Alnylam Pharmaceuticals

ALNY · NASDAQ

$230.71−$2.58 (−1.11%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $233.29

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.

Employees: 2,500
Headquarters: Cambridge, Massachusetts
Listed: May 28, 2004
Sector: Health Care
Industry: Biotechnology
Website: alnylam.com

Leadership

Alnylam Pharmaceuticals executives
Name	Title	Since	Age
Amy Schulman	—	—	64
Yvonne Greenstreet	—	2016	62
Jeffrey Poulton	—	—	57
Kevin Fitzgerald	—	—	57
Robert Hesslein	—	—	71
Pushkal Garg	—	2025	57
Tolga Tanguler	—	—	52
Stuart Arbuckle	—	—	59
Dennis Ausiello	—	—	79
Olivier Brandicourt	—	—	69
Margaret Hamburg	—	—	69
Peter Kellogg	—	—	68
David Pyott	—	—	72
Colleen Reitan	—	—	65
C. Elliott Sigal	—	—	73

Revenue by product and region

Fiscal year ended Dec 31, 2025: $3.71B total revenue

By product

Net product revenues$2.99B80.4%
Net revenues from collaborations$553.37M14.9%
Royalty revenue$174.02M4.7%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Alnylam Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Agilent Technologies A	Supplier and customer	US	0.73
Ironwood Pharmaceuticals A IRWD	Supplier	US	0.66
Veeva Systems A VEEV	Supplier	US	0.65
Centogene CNTG	Supplier and customer	DE	0.62
Arbutus Biopharma ABUS	Supplier and customer	US	0.54
Vir Biotechnology VIR	Supplier and customer	US	0.49
Silence Therapeutics ADR SLN	Supplier and customer	GB	0.45
Benitec Biopharma BNTC	Supplier and customer	US	0.44
Arrowhead Pharmaceuticals ARWR	Supplier and customer	US	0.38
PeptiDream	Supplier and customer	JP	0.36

Similar companies

Companies in the same industry as Alnylam Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.